Skip to content

Two global leaders in patient care join Myka Labs Advisory Board

  • by
Dr. Edward Benz

Longtime Dana Farber Cancer Institute CEO Dr. Edward Benz and Dr. Richard Isaacs, former CEO of Kaiser Permanente, bring extraordinary knowledge and experience

Joining the outstanding group of individuals announced earlier this year as the founding members of the Myka Labs Clinical Advisory Board are:

Dr. Edward Benz. Trained as a clinical hematologist, Dr. Benz is a fellow of the American College of Physicians. His research centers on the molecular basis and genetics of inherited blood disorders like thalassemia. Dr. Benz has served as president of the American Society of Hematology, the Association of American Cancer Institutes, the American Society for Clinical Investigation, the American Clinical and Climatological Association, and the Friends of the National Institutes of Nursing Research. From 2000 to 2016, Dr. Benz served as President and CEO of Dana-Farber Cancer Institute, director and principal investigator of Dana-Farber/Harvard Cancer Center, and a member of the Governing Board of Dana-Farber/Children’s Cancer Center. At Myka Labs, he will guide the company’s current and future initiatives in cancer, including its pipeline expansion beyond the pancreatic and other abdominal cancers where its advanced intraoperative imaging technology is positioned to markedly extend patient lives.

Dr. Richard Isaacs. Dr. Isaacs is Dean of the College of Medicine at California Northstate University. Previously, Dr. Isaacs held the position of CEO at The Permanente Medical Group, the largest medical group in the nation. He also served as the president of The Mid-Atlantic Permanente Medical Group. In these roles, he led 12,000 physicians and 45,000 staff members, overseeing the medical care of 5.4 million Kaiser Permanente members on both the west and east coasts. Dr. Isaacs has been named among Modern Healthcare’s 50 most influential physician leaders and 100 most influential healthcare leaders. Dr. Isaacs is trained in otolaryngology and head and neck surgery, specializing in skull base, head and neck oncologic/microvascular surgery. At Myka Labs, he will provide essential insight on the company’s product initiatives and corporate strategy, including how the company’s technologically advanced products can have a foundational role in future advances in integrated health care delivery.